Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?
Internal Medicine Journal · 2026-05 · 56 (5) · 745-749
DOI: 10.1111/imj.70458 ↗Kurz gefasst
Editorial in der Zeitschrift Internal Medicine Journal, online erschienen am 13.05.2026. Verfasst von Grace Meulman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Edith Collins Centre, Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Edith Collins Centre, Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
- Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Zitieren
APA
Meulman, G., Foran, A., & Roberts, D. M. (2026). Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?. Internal Medicine Journal, 56(5), 745-749. https://doi.org/10.1111/imj.70458
Vancouver
Meulman G, Foran A, Roberts DM. Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?. Internal Medicine Journal. 2026;56(5):745-749. doi:10.1111/imj.70458
BibTeX
@article{Meulman2026,
author = {Meulman, Grace and Foran, Alicia and Roberts, Darren M},
title = {Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?},
journal = {Internal Medicine Journal},
year = {2026},
volume = {56},
number = {5},
pages = {745--749},
doi = {10.1111/imj.70458}
}
EUVIMED